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Angiotensin converting enzyme 2
Interferon signaling
A B S T R A C T
The current new coronavirus disease (COVID-19) has caused globally over 0.4/6 million confirmed deaths/
infected cases across more than 200 countries. As the etiological coronavirus (a.k.a. SARS-CoV2) may putatively
have a bat origin, our understanding about its intermediate reservoir between bats and humans, especially its
tropism in wild and domestic animals are mostly unknown. This constitutes major concerns in public health for
the current pandemics and potential zoonosis. Previous reports using structural analysis of the viral spike protein
(S) binding its cell receptor of angiotensin-converting enzyme 2 (ACE2), indicate a broad potential of SARS-CoV2
susceptibility in wild and particularly domestic animals. Through integration of key immunogenetic factors,
including the existence of S-binding-void ACE2 isoforms and the disparity of ACE2 expression upon early innate
immune response, we further refine the SARS-CoV2 susceptibility prediction to fit recent experimental validation.
In addition to showing a broad susceptibility potential across mammalian species based on structural analysis, our
results also reveal that domestic animals including dogs, pigs, cattle and goats may evolve ACE2-related immu-
nogenetic diversity to restrict SARS-CoV2 infections. Thus, we propose that domestic animals may be unlikely to
play a role as amplifying hosts unless the virus has further species-specific adaptation. Findings may relieve
relevant public concerns regarding COVID-19-like risk in domestic animals, highlight virus-host coevolution, and
evoke disease intervention through targeting ACE2 molecular diversity and interferon optimization.
1. Introduction
Erupting in China last December, the novel coronavirus disease
(COVID-19) has become a worldwide pandemic and caused near 0.4
million confirmed deaths and 6 million infected cases across 200 coun-
tries by the end of May 2020 [1,2]. The etiological virus, designated as
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2) has been
identified [3] and related to the viruses previously causing SARS or
Middle East Respiratory Syndrome (MERS) in humans in 2003 and 2012,
respectively [4]. These three human-pathogenic coronaviruses putatively
evolve from bat coronaviruses, but have different animal tropisms and
intermediate reservoirs before transmission to humans [4, 5]. As civet
cats and camels were retrospectively determined as reservoirs for SARS
and MERS respectively, there is no conclusion about what animal species
passing SARS-CoV2 to humans [4, 5]. Investigations indicated that
Canivora animals including raccoon dogs, red foxes, badgers and minks
as well swine, at a less extent, are susceptible to SARS virus infections [6,
7]. Although the viral nucleic acids and antibodies to MERS were
detectable in multiple ruminant species including sheep, goat, and don-
keys, the virus inoculation studies did not result in a productive infection
for MERS disease in these domestic ruminants, nor in horses [8, 9].
As a group of obligate pathogens, viruses need to engage cell re-
ceptors for entering cells and race with the host immunity for effective
replications and spreading to initiate a productive infection [10]. In this
context, the spike proteins protruding on the coronavirus surface are
responsible for cell receptor binding and mediating viral entry [5, 6, 7].
For example, MERS-CoV adopts the dipeptidyl peptidase 4 (DPP4, a.k.a
CD26) and SARS-CoV uses angiotensin-converting enzyme 2 (ACE2) as
primary receptors for cell attachment and entry [4, 5, 6, 7, 8, 9]. Several
groups have reported that SARS-CoV2 uses the same ACE2 receptor as
SARS-CoV, but exerts higher receptor affinity to human ACE2, which
may ascribe to the efficacy of SARS-CoV2 infection in humans [11, 12].
After cell attachment via the receptor binding domain (RBD) in the
N-terminal S1 region of the S protein, the C-terminal S2 region thus
engages in membrane fusion. Further cleavage of S2 from S1 by a
furin-like protease will release and prime the virus entering the
* Corresponding author.
E-mail address: ysang@tnstate.edu (Y. Sang).




Received 14 July 2020; Received in revised form 18 August 2020; Accepted 26 August 2020
2405-8440/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Heliyon 6 (2020) e04818
receipient cells. Several furin-like proteases, especially a broadly
expressed trans-membrane serine protease 2 (TMPRSS2), are adopted for
priming SARS-CoV entry [11, 12]. Compared with SARS-CoV, studies
showed that SARS-CoV2 spike protein also evolutionarily obtains an
additional furin-like proteinase cleavage site within the S1/S2 junction
region for efficient release from the cell surface and entry into the cells
[3, 11, 12, 13].
Because TMPRSS2 is widely expressed, the tissue-specific expression
of ACE2 has been shown to determine SARS-CoV2 cell tropism in humans
[11, 12]. Namely, human nasal secretory cells, type II pneumocytes, and
absorptive enterocytes are ACE2-TMPRSS2 double positive and highly
permissive to SARS-CoV2 infection [14, 15]. For cross-species animal
tropism, the potential infectivity of SARS-CoV2 in both wild and do-
mestic animals raises a big public health concern after the prevalence of
SARS-CoV2 infections in humans [16, 17]. This concern involves two
aspects: (1) screening to identify the animal species that serve as a virus
reservoir originally passing SARS-CoV2 to humans; and (2) the existing
risk of infected people passing the virus to animals, particularly domestic
species, thus potentially amplifying the zoonotic cycle to worsen
SARS-CoV2 evolution and prevalence [16, 17]. By diagnosis of animals
that in close contact with COVID-19 patients or screening of animal
samples in some COVID-19 epidemic zones, studies detected that do-
mestic cats and dogs could be virally or serologically positive for
SARS-CoV2 [18, 19, 20, 21, 22, 23, 24], as was a reported infection in a
zoo tiger [25]. Using controlled experimental infection of human
SARS-CoV2 isolates, several studies demonstrated that ferrets, hamsters,
domestic cats and some non-human primate species are susceptible to
human SARS-CoV2 strains [18, 19, 20, 21, 22, 23, 24, 25]. Obviously, it
is impractical to test SARS-CoV2 susceptibility experimentally in all an-
imal species. By adoption of a structural simulation based on published
structures of the viral S-RBD/ACE2 complex, studies have predicted a
broad spectrum of vertebrate species with high potential for SARS-CoV2
susceptibility, which, if true, entails unexpected risks in both public and
animal health, and warrants further critical evaluation [26, 27, 28].
ACE2 is a key enzyme catalyzing angiotensin (AGT) further con-
version into numeral active forms of AGT1-9, which are hormonal
mediators in the body's renin-angiotensin system (RAS) [29, 30]. Thus,
ACE2 plays a regulatory role in the blood volume/pressure, body fluid
balance, sodium and water retention, as well as immune effects on
apoptosis, inflammation, and generation of reactive oxygen species
(ROS) [29, 30]. In this line, the expression of ACE2 is also
inter-regulated by immune mediators pertinent to its systemic function.
Multiple physio-pathological factors, including pathogenic inflamma-
tion, influence on RAS through action on ACE2 expression [29, 30, 31].
Interferon (IFN) response, especially that mediated by type I and type III
IFNs, comprises a frontline of antiviral immunity to restrict viral
spreading from the initial infection sites, and therefore primarily de-
termines if a viral exposure becomes controlled or a productive infec-
tion [32]. Most recent studies indicated that SARS-CoV2 evolved viral
antagonisms against IFN responses; however, the viral infections was
significantly inhibited in vitro or at the early phase in vivo using human
IFN-α, IFN-β or type III INF-λ, indicating that IFNs are potential
anti-COVID19 prophylactics [32, 33, 34]. Several recent studies
revealed that human ACE2 gene behaves like an interferon-stimulated
gene (ISG) and is stimulated by a viral infection and IFN treatment;
however, mouse Ace2 gene is not [15, 33, 34]. Therefore, to determine
the cell tropism and animal susceptibility to SARS-CoV2, the
cross-species ACE2 genetic and especially epigenetic diversity in regu-
lation of ACE2 expression and functionality should be evaluated [26,
27, 28, 29, 30, 31, 32, 33, 34]. In this study, through integration of
structural analysis and key immunogenetic factors that show
species-dependent differences, we critically refine the SARS-CoV2 sus-
ceptibility prediction to fit recent experimental validation [16, 17, 18,
19, 20, 21, 22, 23, 24, 25]. Along with showing a broad susceptibility
potential across mammalian species based on structural analysis [26,
27, 28], our results further reveal that domestic animals including dogs,
pigs, cattle and goats may evolve previously unexamined immunoge-
netic diversity to restrict SARS-CoV2 infections.
2. Materials and methods
2.1. Protein and promoter sequence extraction and alignment
The amino acid sequences of ACE2 proteins and DNA sequences of the
proximal promoters of each ACE2 genes were extracted from NCBI Gene
and relevant databases (https://www.ncbi.nlm.nih.gov/gene). ACE2
genes and corresponding transcripts have been well annotated in most
representative vertebrate species. In most cases, the annotations were
double verified through the same Gene entries at Ensembl (http
s://www.ensembl.org). The protein sequences were collected from all
non-redundant transcript variants and further verified for expression
using relevant RNA-Seq data (NCBI GEO profiles). The proximal pro-
moter region spans ~2.5 kb before the predicted transcription (or
translation) start site (TSS) of ACE2 or other genes. The protein and DNA
sequences were aligned using the multiple sequence alignment tools of
ClustalW orMuscle through an EMBL-EBI port (https://www.ebi.ac.uk/).
Other sequence management was conducted using programs at the
Sequence Manipulation Suite (http://www.bioinformatics.org).
Sequence alignments were visualized using Jalview (http://www.ja
lview.org) and MEGAx (https://www.megasoftware.net). Sequence
similarity calculation and plotting were done using SDT1.2 (http://we
b.cbio.uct.ac.za/~brejnev). Other than indicated, all programs were
run with default parameters.
2.2. Phylogenic analysis
The phylogenic analysis and tree visualization were performed using
MEGAx and an online program, EvoView. The evolutionary history was
inferred using the Neighbor-Joining method. Percentage of replicate
trees in which the associated taxa clustered together in the bootstrap test
(1,000 replicates) was also performed. The evolutionary distances were
computed using the p-distance method and in units of the number of
amino acid differences per site. Other than indicated, all programs were
run with default parameters as the programs suggested.
2.3. Structural simulation and analysis
The structure files of human ACE2 protein and its interaction with
SARS-CoV2 S-RBD were extracted from the Protein Data Bank under the
files of 6M17 and 6M0J. The residual mutation and structure simulation
were performed using UCSF Chimera and Pymol available at http
s://www.cgl.ucsf.edu/chimera/ and https://pymol.org/, respectively.
Structural visualization were using Pymol. The binding affinity energy
(ΔG), dissociation constant (Kd) and interfacial contacts between S-RBD
and each ACE2 were calculated using a PRODIGY algorithm at https://bi
anca.science.uu.nl/prodigy/.
2.4. Profiling transcription factor binding sites in ACE2 promoters and
PWM scoring
The regulatory elements (and pertinent binding factors) in the ~2.5
kb proximal promoter regions were examined against both human/ani-
mal TFD Database using a program Nsite (Version 5.2013, at http:
//www.softberry.com). The mean position weight matrix (PWM) of
key cis-elements in the proximal promoters were calculated using PWM
tools through https://ccg.epfl.ch/cgi-bin/pwmtools, and the binding
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motif matrices of examined TFs were extracted from JASPAR Core 2018
vertebrates (http://jaspar.genereg.net/).
2.5. RNA-Seq and data analysis
For expression confirmation, several sets of RNA-Seq data from NCBI
Gene databases, and one of ours generated from porcine alveolar
macrophages (BioProject with an accession number of SRP033717), were
analyzed for verification of the differential expression of ACE2 genes in
most annotated animal species. Especially, the expression of porcine
ACE2 isoforms and relevant other genes in the porcine lung macrophage
datasets. Significantly differentially expressed genes (DEGs) between two
treatments were called using an edgeR package and visualized using
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Figure 1. Incongruence of predicted SARS-CoV2 susceptibility to experimental data in selected major livestock and reference animal species. Protein sequences of
angiotensin converting enzyme 2 (ACE2) orthologs in different species, and transcript variants identified within some species, were extracted from NCBI (and
Ensembl) Gene databases and verified using relevant RNA-Seq expression. (A) Sequence alignment was performed with ClustalW and pairwise identity (%) was
calculated and visualized using SDT1.2. The reciprocal proteins for comparison on the horizontal are the same order as the vertical. Only NCBI Accession numbers are
listed, see the common names in (B). (B) The phylogenic tree of major identified ACE2 orthologs/variants from different species was built with a Neighbor-joining
approach and visualized using an EvoView program under default parameter setting. The prediction of SARS-CoV2 susceptibility is based on the sequence similarity of
each ACE2 to human ACE2 in the S-RBD binding region and simulated using a published human ACE2-RBD structure (6M0J) and refers to two recent publications
using similar procedures but different structural models [27, 28]. Compared with the currently available experimental data, incongruence of the predicted SARS-CoV2
susceptibility is clearly demonstrated in pangolin, ferret, tiger, cat and horseshoe bat, indicating that some other factors besides ACE2-RBD affinity should
be considered.
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Human Q24 D30 K31 H34 E35 E37 D38 Y41 Q42 N53 L79 M82 Y83 N330 K353 G354 D355 R357 R393 %
Macaque - - - - - - - - - - - - - - - - - - - 100
Ferret L E - Y - - E - - - H T - - - R - - - 63
Hamster - - - Q - - - - - - - N - - - - - - - 89
Cat L E - - - - E - - - - T - - - - - - - 84
Tiger L E - - - - E - - - - T - - - - - - - 84
Dog-L L E - Y - - - - - - - T - - - - - - - 84
Dog-S - - - - - - 32
Pangolin E E - S - - E - - - I N - - - H - - - 63
C.H.Bat L - - T K - - H - - - N - - - - - - - 74
Pig-L L E - L - - - - - - I T - - - - - - - 84
Pig-S - - - - - - 32
Sheep - E - - - - - - - - M T - - - - G - - 79
Goat-L - E - - - - - - - - M T - - - - - - - 84
Goat-S M T - - - - - - - 32
Cale-L - E - - - - - - - - M T - - - - - - - 84
Cale-S M T - - - - - - - 32
Horse L E - S - - E H - - - T - - - - - - - 68
Alpaca L K E - - - - - - - A I - - - - - - - 74
Bison - E - - - - - - - - M T - - - - - - - 84
Rabbit L E - Q - - - - - - - T - - - - - - - 79
G. Panda L E - Y - - - - - - H T - - - - - - - 74
Oer L E - Y - - E - - - N T - - - R - - - 63
Camel L E E - - - - - - - T T - - - - - - - 74
Civet L E T Y - - E - - - - T - - - - - - - 68
Mouse N N N Q - - - - - - T S F - H - - - - 58
Rat K N - Q - - - - - - I N F - H - - - - 63
Chicken E A E V R - - - E - N R F - - N - - - 47
A.C. Frog - K R Q - - V H - - N A F - M N - - - 47
Zebrafish R N - E - S - - - D E A - - N K - - - 53
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Figure 2. Prediction of SARS-CoV2 susceptibility in major livestock species based on the conservation of key interacting residues and binding capacity between the
viral spike (S) protein on the host ACE2 receptor. (A) SARS-CoV-2 uses the cell receptor, angiotensin-converting enzyme 2 (ACE2) for entry and the serine protease
TMPRSS2 and furin for S protein priming. (B) As TMPRSS2 is broadly expressed and active with a furin-like cleavage activity, the affinity adaption of the S receptor
binding domain (RBD) and ACE2 receptor determines the viral permissiveness. The contacting residues of human ACE2 (a distance cutoff 4.5 Å) at the SARS-CoV-2
RBD/ACE2 interfaces are shown, and the contacting network involves at least 19 residues in ACE2 (listed in the Table cells and referred to the aligned residual
positions in human ACE2) and 10 residues in the SARS-CoV-2 RBD (blue circles with residue labels), which are listed and connected with black lines (indicating
hydrogen bonds) and red line (represents salt-bridge interaction). The cross-species residual identity (%) of these interacting residues in ACE2 are listed in a broad
range (32–100%) [26, 27, 28]. (C) We also detected several short ACE2 isoforms (underlined) in the domestic animals including dog, pig, goat and cattle, which have
an N-terminal truncation spanning 10–13 key residues in the contacting network to S-RBD but keeping the enzyme active sites (indicated by Yellow triangles), thus
resulting in little engagement by the viral S protein and predicting an unexpected evolutionary advantage for relieving potential COVID-19 risk caused by the viral
engagement and functional distortion on the classical long ACE2 isoforms in these animal species. The NCBI Accession Numbers of the ACE2 orthologs are listed as
in Figure 1.
ACE2-CoV2 S-RBD Human Bat Ferret Hamster Cat Average Dog-L Pig-L Cale-L Sheep-L Horse Mouse
(6M0J) (Goat-L)
Binding E. (∆G, kcal/mol): -11.9 -11.2 -12.9 -12.1 -12.2 -12.1 -12.3 -12.1 -12.5 -12.8 -11.6 -12.1
Kd (M) at 25.0 : 1.90E-09 6.40E-09 3.40E-10 1.30E-09 1.10E-09 2.21E-09 9.30E-10 1.40E-09 6.90E-10 3.90E-10 3.30E-09 1.90E-09
Interfacial contacts (ICs):
ICs charged-charged: 3 2 4 2 3 3 2 2 3 3 2 0
ICs charged-polar: 10 12 13 10 10 11 9 9 10 8 13 10
ICs charged-apolar: 18 16 25 16 19 19 19 17 19 18 18 7
ICs polar-polar: 4 4 2 5 2 3 2 2 4 4 3 6
ICs polar-apolar: 21 19 20 24 20 21 21 21 23 25 19 29

































E Table 1. Predicon of binding affinity energy (ΔG), dissociaon constant (Kd) and interfacial contacts of the SARS-CoV2 
S-RBD with ACE2 orthologs of major livestock species simulated using the human ACE2/CoV2-RBD structure (6M0J).
Figure 3. Binding capacity of SARS-CoV2 spike protein (S) and its cell receptors (ACE2) from different animal species. (A) Structure of the receptor-binding domain
(RBD) of S from SARS-CoV2 (cyan) bound to human angiotensin-converting enzyme 2 (ACE2) (blue). Most residues involved in binding are highlighted as magenta
(ACE2) or orange (S) sticks and labeled as one-letter amino-acid codes plus residual numbers in bold or regular font respectively for S or ACE2 residues. The dotted/
blue lines indicate intermolecular salt bridge or hydrogen bonds between interacting residues (generated and visualized with UCSF Chimera and Pymol from Protein
Data Bank File 6M0J). (B) to (D) RBD interaction with the simulated structures of ACE2 long isoforms from the dog, pig and cattle, respectively. Amino acid exchanges
in ACE2 from another species compared with human ACE2 are highlighted in red. (E) Prediction of binding affinity energy (ΔG), dissociation constant (Kd) and
interfacial contacts of the SARS-CoV2 S-RBD with ACE2 orthologs of major livestock species. Most domestic animals ACE2 including that from mouse and rat (species
known not to be susceptible to SARS-CoV2) have a binding affinity (ΔG) at -11.2 to -12.8 kcal/mol that is within the range (11.2–12.9 kcal/mol) between the RBD and
the ACE2 from the known susceptible species (underlined in the left part of the table), indicating that some other factors, especially those from genetic divergence and
natural immunity, contribute to the SARS-CoV2 susceptibility of different animal species.
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Figure 4. Detection of several short ACE2 isoforms (ACE2-S) in the domestic animals including dog, pig, goat and cattle. (A) In contrast to most splicing isoforms such
as in cats and humans, which share a common proximal promoter and encode ACE2 proteins with similar sequences containing all 19 key RBD-interacting residues,
these short ACE2-S isoforms in domestic animals truncate for 71 (Cattle/Goat ACE2-S) or 132 (Dog/Pig ACE2-S) residues at their N-termini compared with human
ACE2 or the long ACE2 isoforms in these species, thus destroying 10–13 key residues in the contacting network to S-RBD but retaining all enzyme active sites (Yellow
triangles in the blue ACE2 domain bar). This results in little chance to be engaged by the viral S protein binding and predicts an unexpected evolutionary advantage to
relieve potential COVID-19 risk caused by the viral engagement and functional distortion on the classical long ACE2 isoforms in these animal species. (B), (C) and (D)
Paired structural comparison between the human ACE2 structure (6M17) with each simulated ACE2-S structure from pig (B), dog (C) and cattle/goat (D). Human
ACE2 structure are in green, and each compared animal ACE2-S structure in magenta. The N-terminal residues of both compared structures are in cyan (arrows
indicating N-termini of the ACE2-S isoforms) and shared C-termini are in red. The 19 key S-interacting residues in human ACE2 are shown in blue sticks. In general, all
ACE2-S orthologs, particular the porcine, show high structural similarity to the human ACE2 except the N-terminal truncations.
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3. Results and discussions
3.1. Vertebrate ACE2 orthologs share an functional constraint but
experience intra-species diversification in livestock with unknown selective
pressure
Sequence comparison among ACE2 orthologs across 30 representa-
tive vertebrate species shows a pairwise identity range at 57–85%
(Figure 1A and Supplemental Fig. S1 and Excel Sheet), which is 15–27%
higher than the average value generated through a similarity analysis at
30–70% on gene orthologs at a genome-wide scale [37]. This indicates
that ACE2 exerts a similar and basic function cross-species, consistent
with its systemic and regulatory role as a key enzyme in RAS, an essential
regulatory axis underlying the body circulatory and execratory systems in
vertebrates [29, 30, 31]. A comparison of evolutionary rates of major
genes within RAS including angiotensinogen (AGT), ACE, and several
receptors of the processed angiotensin hormones showed that ACE2
actually evolves slightly faster than ACE [ 36, and unpublished data].
This implies that ACE2 may bear pressure for RAS adapting evolution per
a species-dependent physiological and pathological requirement [29, 30,
31]. This evolutionary adaptability of ACE2 genes is demonstrated by the
existence of numerical genetic polymorphisms [38] and several tran-
script isoforms particularly in humans and major livestock species
(Figure 1B and Supplemental Fig. S1 and Excel Sheet). We identified (and
verified by RNA-Seq data analysis) four transcripts of ACE2 isoforms in
humans (Figure 1B) that primarily differ in the C-terminal 50 residues
within the collectrin domain. Particularly, 1–2 short ACE2 isoforms were
identified in dogs, pigs, cattle, and goats in addition to the longer ACE2
consensus to the human's (designated as –S or –L, respectively after the
animal common names in Figure 1B and thereafter). These livestock
ACE2-S isoforms have a 70–130 residual truncation at their N-terminal
peptidase domains, which also span the region interacting with
SARS-CoV spike protein. The selective mechanisms driving the evolution
of these short ACE2 isoforms in livestock are unknown, but may relate to
previous pathogenic exposure or unprecedented physio-pathological
pressure. To support this reasoning, short ACE2 isoforms are detected
in both domestic Bos taurus and hybrid cattle, but not in the wild buffalo
and bison; and ACE2 isoforms from each species are generally paralogous
and sister each other within a clade in the phylogenic tree (Figure 1B).
3.2. Incongruence of predicted SARS-CoV2 susceptibility to experimental
data in selected major livestock and reference animal species
Phylogenic analysis of vertebrate ACE2 orthologs/paralogs reveals a
general relationship aligning to the animal cladistics (Figure 1B). In this
context, homologs from the fish, frog and chicken conform to a primitive
clade. All ungulate homologs form into parallel clades next to each other.
The homologs from the glires, primates and carnivores cluster into a big
clade (marked with yellow triangle node), which contains all the SARS-
CoV2 susceptible species that have been verified via natural exposure
or experimental infections (Figure 1B, marked with red/orange circles).
We examined and merged several previous studies about the prediction
of SARS-CoV2 susceptibility in vertebrates based on the simulated
structural analysis of S-RBD-ACE2 complex [26, 27, 28]. As numerous
vertebrate species were predicted to be high or low potential (Figure 1B,
labeled as red H or green L) for SARS-CoV2 susceptibility, incongruence
between the predicted SARS-CoV2 susceptibility and infected validation
is apparent in pangolin, ferret, tiger, cat and horseshoe bat, indicating
that some other factors besides ACE2-RBD affinity should be considered
[15, 32, 33, 34]. We, therefore, refined the prediction matrix to include
the RBD-binding evasion of some ACE2 orthologs identified in major
livestock species and the interferon-stimulated ACE2 expression in
priming SARS-CoV2 infections [15, 32, 33, 34].
3.3. A broad SARS-CoV2 susceptibility potential based on structural
analysis
Several recent studies have elegantly demonstrated the structural
interaction of the viral S protein or its RBD in complex with human ACE2
receptor [39, 40]. Showing that the contacting residues at the RBD/ACE2
interface (Figure 2A) involve at least 19 residues in ACE2 (Figure 2B,
listed in the Table cells and referred to the aligned residual positions in
human ACE2) and 10 residues in the SARS-CoV-2 RBD (Figure 2B, blue
circles with residue labels above the Table) [28, 39, 40]. The
cross-species residual identity (%) of these interacting residues in ACE2
are dispersed in a broader range (32–100%) than the whole ACE2
sequence identity rate at 57–85% [37], indicating a faster evolution rate
of this virus-interacting region. Notably, the S-binding region spans a
large part of the N-terminal peptidase domain, thus S-binding may
competitively block a majority of active sites to inhibit the physiological
action of ACE2 (Figure 2C).
Using a similar structural analysis procedure [27, 28], we modeled
the ACE2 structures of animal species of interest and simulated their
interaction with SARS-CoV2 S-RBD based on a published RBD-human
ACE2 structure (Protein Data Bank File 6M0J) [39]. Figure 3 demon-
strates the S-RBD interaction with the simulated structures of ACE2 long
isoforms from the dog, pig and cattle, respectively. The major changes of
the RBD-ACE2 interacting interfaces are from the residual exchanges in
ACE2 from other species compared with human ACE2 (Figure 2B-2D,
highlighted in red). In addition, the exchange of N90T (in pigs) and
N322Y (in cattle and sheep) would destroy the N-glycosylation site in
human ACE2. ACE2 from goat (Supplement Fig. S1) exhibits identical
amino acid exchanges as in cattle in the RBD-ACE2 interfacial contacts. In
contrast, when compared with human ACE2, ACE2 from cats (Supple-
ment Fig. S1) conserves all relevant glycosylation sites in human ACE2
[28,39]. We also calculated the interfacial contacts using parameters of
protein-protein interaction including the predictable binding affinity
energy (ΔG), dissociation constant (Kd) and number of different inter-
facial contacts within the S-RBD and ACE2 contact. Although the exact
numbers may differ from the previous reports [39], they provide a very
comparable matrix generated using the same algorithm (Figure 3E) [41].
Data show that the ACE2 of most domestic animals, including that from
mouse and rat (the species known to be unsusceptible to human
SARS-CoV2) have a binding affinity (ΔG) at -11.2 to -12.8 kcal/mol. This
is within the binding affinity range (11.2–12.9 kcal/mol) between the
RBD and the ACE2 from known susceptible species (Figure 3E, under-
lined in the left part of the table). This indicates that other factors,
conceivably from genetic divergence and/or natural immunity, also
contribute to SARS-CoV2 susceptibility in animal species. Therefore, an
effective prediction matrix should include the critical immunogenetic
factors to further determine virus susceptibility in addition to the
sequence/structural similarity of ACE2 receptors (Figure 1 and Fig. S1)
[15,34,38].
3.4. Identification of livestock short ACE2 isoforms that likely evade the
binding by SARS-CoV2 spike protein
We detected several short ACE2 isoforms in the domestic animals
including dog, pig, goat and cattle that have an N-terminal truncation
spanning 10–13 key residues in the contacting network to S-RBD but
retain the enzyme active sites (Figure 4A). Most of the splicing isoforms
from ACE2 genes such as in zebrafish, cats and humans, share a common
proximal promoter and encode ACE2 proteins containing all 19 key RBD-
interacting residues [39, 40]. However, these short ACE2-S isoforms in
domestic animals truncate for 71 (Cattle/Goat ACE2-S) or 132 (Dog/Pig
ACE2-S) residues at their N-termini compared with the long ACE2 iso-
forms in the same species (Figure 1 and Fig. S1). Therefore, these short
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-2.0              -1.8               -1.6              -1.4               -1.2               -1.0               -0.8              -0.6               -0.4              -0.2               0.0
TSS/ATG
Putave proximal promoter region 
10 9 8 7 6 5 4 3 2 1 0 (ACE2-P)
●3□ ●● ◊(STAT) ●● ◊(IRF/ISRE) ● ● ● Human*
◊●3 ●3 ●● ● ●◊ ● ●4 ◊ ◊● ●5 ●●○ Macaque*
◊●3 ●● ●□ ●● ○● ● ●4 ●3 ●3◊ ● ● Ferret*
●4 ●●◊ ●◊ ●●□ □●● ●● ●● ●● ●● ● ● Hamster*
●● ●3 ● ●● ●3□□ ◊□ □○●3 ● ●● ● ● Cat
●4 ●3 ●3□ ●● □●● ○3● ●●□ ◊● ●● ● ● Tiger
●4 ●● ●● ●3 ●4 □●4 ●● □●● ●● ◊● ●5 Dog-L
□●4 ●5 ●● ●5 ●4 ●4 ●● □●4 □●●◊ ●3 ● Dog-S
□●4 ●3 ◊●3 ●● ● ●● ●3◊ ●● ●● ●○ Pangolin
●4 ●4 ●3□ □● ● ●3 ◊● ● ●● ○4●5 ●◊ G.H. Bat
●4□◊ ◊ ● □ ● ●●○ ●9○ ● Mouse
◊◊●6 ● ● ●○ ● ○3 ● ●● ● Rat
◊●3 ◊●5 ● ● ◊● ◊●● ◊●● ◊□ ●● ●4 ◊●3 Pig-L
●4 ●4 ● ●6 ● ●3 ●5 □□● ●4 ● ●● Pig-S
●5 ◊●3 ● ●● ●4 ●5 ●4 ● ●● ●● ● Sheep
○●4 ● ●3 ● ●● ●3 ● ●● ●● Goat
○●5 ●3□ ●● ●● ● ●● ●●□ ●3 ● ● ●○ B. taurus
○●5□ ◊●● ●● ●● ●● ●●□ ● ●● ●● B. hybrid
●5□◊ ●● ● ●● ●3□ ●● ● ● ● ● B. indicas
●6 ●3 ●●□□ ●● ● ● ●4 ◊ ●5 ●● Horse
◊●4 ●● □●● ◊● ●● ● ● ●3 ●● ●● Alpaca
●5□◊ □● ●● ● ●● ●● ●● ● ● Bison
◊●3 ●6 ● ●●◊□ □● ●● ●3 ○●8 □●3 ●3 ●3 Rabbit
□●3 □●4 ● □● ● ●○ ● ● □●5 ●3◊ G. Panda
●3 ●● □●● ●3 ○● ● ○●3 ●3 ●◊ ●● ● Oer
◊●3 ●● ● □ ● ◊● □● ●● ●● ●● ●● Camel
●4○ □● ◊●3 ●3□◊○ ● □ ●●□ ●● ◊● ●● ●● Chicken
●3 ◊● ● ● ●● ●3 ●● ●6□ ●4 ●●□ A.C. Frog
◊◊ ◊●6 ◊□ ◊□ □2●3 Zebrafish
◊3□2● ●4 ◊● ●3◊ ●3 ●◊ ● ●●○ ● ●4 ●● (ISG15)
○●4 ● ●3□ ◊ ● ● ● ● □ ●● ●○ (IRF1)
Figure 5. Categorizing ACE2 genes based on regulatory cis-elements predicted in their proximal promoter regions (<2 Kb before TSS or ATG). The regulatory el-
ements (and pertinent binding factors) in the ~2 kb proximal promoter regions were examined against both human/animal TFD Database using a program Nsite
(Version 5.2013, at http://www.softberry.com), including ACE2 genes identified in major livestock animals and several reference animal species. Data show that
animal ACE2 gene promoters are evolutionally different in containing IFN- or virus-stimulated response elements (ISRE, PRDI, IFRs, and/or STAT1/3 factors) and cis-
elements responsive to pro-inflammatory mediators, which mediate different ACE2 responses to antiviral interferons (IFNs) and inflammation associated with COVID-
19 disease. Legend: ○, GATA-1 regulating constitutive expression; , acute (◊) or secondary (◊) IFN-stimulated response element (ISRE) and PRDI that interact with IRF,
ISGF3 and STAT factors, respectively; □, cis-elements interacting with factors to mediate immune/inflammatory responses including C/EBP, NF-kB, NF-IL6, and p53;
●, cis-elements reacting with other factors significant in other developmental/physiological responses. The promoter features of two typical human interferon-
stimulated genes (ISG), the robust ISG15 and tunable IRF1 are shown as references to indicate that ACE2 genes obtain species-different ISG propensity responsive
to IFN and inflammatory stimuli.
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ACE2 isoforms destroy 10–13 key residues in the contacting network to
S-RBD but likely retain ACE2 enzymatic function in RAS. Paired struc-
tural comparison between the human ACE2 structure (extracted from
6M17) with each simulated ACE2-S structure from the pig, dog, and
cattle/goat, reveals that all these ACE2-S orthologs from domestic ani-
mals, particularly the porcine one, show high structural similarity to the
human ACE2 except for the N-terminal truncations (Figure 4B-4D). This
indicates that these short ACE2 isoforms in domestic animals have little
chance to be engaged by the viral S-binding, and predict an unexpected
evolutionary advantage to allay potential COVID-19 risk resulting from
viral engagement and functional distortion on the classical long ACE2
isoforms in these animal species [38, 42].
3.5. ACE2 genes in vertebrates obtain different propensity in response to
viral infection and interferon stimulation
SARS-CoV2 infection induces a weak IFN response but a production of
high amount of inflammatory cytokines including interleukin (IL)-6 and
chemokine CXCL10 in most severe COVID-19 patients [43, 44, 45, 46].
Studies of SARS and MERS showed that these pathogenic coronaviruses
share similar viral antagonisms including the endoribonuclease (EndoU)
encoded by nonstructural protein 15 (nsp15), which directly blunts cell
receptors responding to viral dsRNA and in turn weaken the acute anti-
viral response [47]. Several recent studies revealed that SARS-CoV2
seems more cunning in not only evading or antagonizing but also in
exploiting the IFN response for efficient cell attachment [15, 43, 44,
47]. As a key enzyme in RAS, the expression of ACE2 gene has been
primarily investigated for physiological response to circulatory
regulations, and a response to pathological inflammation is also
expected [29, 30, 31]. However, the expression of human ACE2 gene
was highly responsive to both viral infection and host IFN response,
i.e. human ACE2 gene seems an unstudied IFN-stimulated gene (ISG)
[15, 33]. Surprisingly, the ISG propensity of
ACE2 genes is species-dependent, for examples, the mouse Ace2 gene is
less IFN responsive, which may partly explain the mouse insusceptibility
to SARS-CoV2 infection [15].
To categorize the different IFN-inductive propensity of ACE2 genes in
vertebrates, particularly in major livestock species, we profiled the reg-
ulatory cis-elements and relevant transcription factors in the proximal
promoter regions of each ACE2 genes (2.5 Kb before TSS or ATG).
Figure 5 illustrates major regulatory cis-elements located in ACE2 genes
from major livestock animals and several reference animal species. Data
show that animal ACE2 gene promoters are evolutionally different in
containing IFN- or virus-stimulated response elements (ISRE, PRDI, IFRs,
and/or STAT1/3 factors) and cis-elements responsive to pro-
inflammatory mediators. All these cis-elements recruit corresponding
transcription factors (TF) to mediate differential ACE2 responses to
antiviral IFNs and inflammation that is associated with COVID-19
disease [2, 3, 48]. We discover that ACE2 genes obtain
species-different ISG propensity responsive to IFN and inflammatory
stimuli. In most (if not all) of the SARS-CoV2 susceptible species, the
ACE2 genes obtained the IFN-responsive elements between the typical
robust and tunable IFN-stimulated genes (ISG) [49]. In general, the
robust ISGs (ISG15 as an example here) are stimulated in the acute phase
of viral infection and play a more antiviral role; in contrast, the later
responsive tunable ISGs (IRF1 as an example) contribute more to
anti-proliferation of IFN activity [49]. In addition, unlike the promoter of
the short ACE2 isoforms in cattle and goats, which share most common
promoter regions with their paralogous long isoforms, the short ACE2
isoforms of dogs (Dog-S) and pigs (Pig-S) have distinct proximal pro-
moter regions (and different IFN responsivity) to the paralogous long
ACE2 isoforms (Figures 5 and 6). Results indicate that the short ACE2
isoforms in pigs and dogs diversify from their long paralogs at both the
levels of genetic coding and epigenetic regulation to adapt to some
evolutionary pressure, such as that from pathogenic interaction
(Figure 7) [38,50].
3.6. Matrix scores of interferon-inductive elements in ACE2 gene promoters
correspond to SARS-CoV2 susceptibility
The position weight matrix (PWM) stands as a position-specific
scoring model for the binding specificity of a transcription factor (TF)
on the DNA sequences [51]. Using PWM toolsets online (https://ccg.epfl.
ch/cgi-bin/pwmtools), we evaluate mean PWMof key cis-elements in the
proximal promoters of ACE2 genes that containing binding sites for ca-
nonical IFN-dependent transcription factors, which include ISRE/STAT,
IRF1. IRF3/7 and IRF8, as well as C/EBP representing a core transcription
factor for pro-inflammation. These IFN-dependent transcription factors,
particularly IRF3/7 and ISRE/STAT for IFN stimulation, are differentially
enriched in the promoter regions of ACE2 genes in a species-dependent
way. Higher enrichment of ISRE/STAT1/3 and/or IRF3/7 binding sites
are detected in most SARS-CoV2/COVID19 susceptible species (indicated
with solid orange or red circles, respectively). In contrast, the PWM for
IRF1 and C/EBP, which regulate inflammation, are less differential in
ACE2 promoters from different animal species, indicating that ACE2
genes are more universally regulated by inflammation than that by the
viral infection or IFN-induction in a species-dependent way (Figure 6). As
compared with the promoters of a typical human robust ISG15 and
tunable IRF1 genes, this data indicate that ACE2 genes (particularly the
primate ones) are not typical robust or tunable ISGs as represented by
ISG15 or IRF1, but respond differently to viral infection (through IRF3/7)
or IFN auto-induction (via ISRE/STAT) in a species-dependent manner
(Figure 6) [49]. Higher enrichment of ISRE/STAT1/3 and/or IRF3/7
corresponds to SARS-CoV2 susceptibility in experimentally validated
mammalian species especially primates, but not to the phylogenically
distant species such as zebrafish, which has very low potential for
SARS-CoV2 susceptibility due to the high disparity of ACE2 structures
(Figure 1 and Fig. S1). In addition, the proximal promoters of the pig and
dog ACE2-S genes differ much in their IFN-responsive elements to most
ACE2 promoters in mammalians (Figures 5 and 6). However, they are
phylogenically sister to the ACE2 promoters from the primitive verte-
brates (frog, chicken and zebrafish) (Figure 7, phylogenic tree). This
indicates that the expression of these short ACE2 isoforms is more con-
servative than the long ACE2 paralogs, which represent a more recent
evolution obtaining ACE2 epigenetic regulation by IFN-signaling
(Figure 7) [50].
3.7. Integrating ACE2 structural analysis, isoforms variants, and
interferon-association for SARS-CoV2 susceptibility prediction and
validation
Studies show that affinity adaption of the viral S-RBD and ACE2 re-
ceptor determines the cellular permissiveness to the virus [28, 39, 40].
SARS-CoV2 not only adapts a high binding affinity to human ACE2 for
cell attachment, but also antagonizes host antiviral interferon (IFN)
response and utilizes IFN-stimulated property of human ACE2 gene to
boost spreading [15, 39, 40, 50]. In addition to structural analysis of
simulated S-RBD-ACE2 interaction, we propose that several immunoge-
netic factors, including the evolution of S-binding-void ACE2 isoforms in
some domestic animals, the species-specific IFN system, and epigenetic
regulation of IFN-stimulated property of host ACE2 genes, contribute to
the viral susceptibility and the development of COVID-19-like symptoms
in certain animal species [15, 39, 40, 50]. A computational program in
development that incorporates this multifactorial prediction matrix and
in vitro validation of SARS-CoV2 susceptibility in major vertebrate spe-
cies will be necessary to address public concerns relevant to SARS-CoV2
infections in animals (Figure 7). It will also lead to the development of
better animal models for anti-COVID19 investigations [21]. In addition,
several IFN-based therapies for treatment of COVID19 have been pro-
posed and are in the process of clinic trials [52, 53, 54, 55]. Considering
the viral stealth of IFN-stimulated property of human ACE2, a timely and
subtype-optimized IFN treatment should be delivered than a general
injection of typical human IFN-α/β subtypes [52, 53, 54, 55]. In this line,
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domestic livestock like pigs and cattle have a most evolved IFN system
containing numerous unconventional IFN subtypes. Some of these un-
conventional IFN subtypes, such as some porcine IFN-ω exert much
higher antiviral activity than IFN-α even in human cells and most IFN-λ
retaining antiviral activity with less pro-inflammatory activity, could be
utilized for developing effective antiviral therapies [56, 57]. In summary,
a predication matrix, which integrates the structural analysis of
S-RBD-ACE2 interfacial interface and the species-specific immunogenetic
diversity of ACE2 genes, was used to predict the SARS-CoV2 suscepti-
bility and fit current knowledge about the infectious potential already
validated in different animal species (Figure 7). More extensive valida-
tion experiments are needed to further improve this prediction matrix.
Our current results demonstrate several previously unstudied immuno-
genetic properties of animal ACE2 genes and imply some domestic ani-
mals, including dogs, pigs and cattle/goats, may obtain some

































































































































































Figure 6. Scores of mean position weight matrix (PWM) of key cis-elements in the proximal promoters of ACE2 genes that containing binding sites for canonical IFN-
dependent transcription factors, which include ISRE/STAT1/3, IRF1, IRF3/7 and IRF8, as well as C/EBP as a core transcription factors for pro-inflammatory response.
These IFN-dependent transcription factors, particularly IRF3/7 and ISRE/STAT critical for IFN stimulation, are differentially enriched in the promoter regions of ACE2
genes in a species-dependent way. Especially, increased enrichment of ISRE/STAT1/3 and IRF3/7 binding sites are detected in the SARS-CoV2/COVID19 susceptible
species (indicated with solid orange or red circles, respectively). In contrast, the PWM for IRF1 and C/EBP, which regulate inflammation, are less differentially
enriched in ACE2 promoters from different animal species. The promoters of a typical human robust interferon-stimulated gene (ISG) 15 and IRF1 (a typical tunable
ISG) are used as references. Higher enrichment of ISRE/STAT1/3 and IRF3/7 corresponds to SARS-CoV2 susceptibility in experimentally validated animal species and
humans. Abbreviations: C/EBP, CCAAT/enhancer binding protein; IRF, interferon-regulatory factor; ISRE, Interferon-sensitive response element; STAT, Signal
transducer and activator of transcription; PWM, position weight matrix. The PWM tools are used through https://ccg.epfl.ch/cgi-bin/pwmtools.
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COVID19 risk than previously thought. However, immediate biosecurity
practices should be applied in animal management to reduce animal
exposure to the virus and prevent potential species-specific adaptation
(Figure 7). For livestock breeding programs that targeting disease resis-
tance to respiratory viruses, the genetic and epigenetic diversity of ACE2
genes as well antiviral ISGs are highly recommended [49, 50, 56, 57].
In conclusion, SARS-CoV2 evolves to fit well with human (and non-
human primates) ACE2 receptor through the structural interfacial affin-
ity, immunogenetic diversity and epigenetic expression regulation,
which results in a highly infectious efficacy [1, 2, 3, 15, 28, 39, 40]. Most
mammalian animals, especially those that belong to glires, primates and
carnivores, have a higher potential for SARS-CoV2 susceptibility but in a
species-different manner based on the existence of S-binding-void ACE2
isoforms and the difference of the IFN-inductive propensity of the major
ACE2 genes. Most ungulate animals appear have a low susceptibility
potential with horses and sheep having a high potential (Figure 7).
Current development of IFN-based anti-COVID19 therapies should
consider the ISG property of human ACE2 gene to optimize for timely
application using a highly-antiviral subtype that potentially have less
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Figure 7. Prediction matrix and in vitro
validation of SARS-CoV2 susceptibility in
major vertebrate species based on (1) the
binding capacity of the viral spike RBD on
host ACE2 receptor; (2) the promotion of
animal ACE2 gene by the interferon response.
Studies show that affinity adaption of the
viral Spike receptor binding domain (RBD)
and ACE2 receptor determines the viral sus-
ceptibility. SARS-CoV2 not only adapts a
high binding affinity to human ACE2 for cell
attachment, but also antagonizes the host
antiviral interferon (IFN) response and uti-
lizes the IFN-stimulated property of human
ACE2 gene to boost spreading.
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evolution of the IFN complex and functional diversity in domestic ani-
mals (such as pigs and cattle) provides a natural model for optimizing IFN
antiviral regulation and therapy development [56, 57].
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